Effects of trastuzumab emtansine on canine urothelial carcinoma cells in vitro and in vivo
Veterinary and Comparative Oncology · 2024
DOI: 10.1111/vco.12970 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary and Comparative Oncology, 2024. Verfasst von Kosei Sakai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Small Animal Clinical Medicine, Graduate School of Veterinary Sciences, Osaka Metropolitan University, Osaka, Japan. Hauptthemen laut MEDLINE: Dog Diseases, Trastuzumab, Ado-Trastuzumab Emtansine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Urothelial carcinoma (UC) is the most common malignancy of the urinary tract in dogs and has aggressive behaviour. Although human epidermal growth factor receptor 2 (HER2) is a known therapeutic target with evidence in canine UC, the efficacy of anti‐HER2 antibody drugs remains unknown. This study aimed to investigate the effects of anti‐HER2 antibody drugs including trastuzumab and trastuzumab emtansine (T‐DM1) on canine UC cell lines in vitro and in vivo. Four canine UC cell lines (Nene, TCCUB, Love, and Sora) were used. In western blotting, HER2 protein expression was observed in all the cell lines. Although both trastuzumab and T‐DM1 showed dose‐dependent growth inhibitory activity in the cell lines, T‐DM1 showed much stronger activity than that of trastuzumab. In flow cytometry analyses with the canine UC cell line (Sora), T‐DM1 but not trastuzumab significantly increased the percentages of early and late apoptotic cells in annexin V apoptotic assays and the sub‐G1 phase fraction in cell cycle analyses. For the in vivo experiment, the canine UC cells (Sora) were subcutaneously injected into nude mice. Four days after inoculation, trastuzumab, T‐DM1, or vehicle was administered intraperitoneally once a week for three times. Tumour volumes were significantly smaller in the T‐DM1 group compared to the trastuzumab and vehicle control groups. These findings indicate that T‐DM1 exerts a stronger antitumour effect than that of trastuzumab on canine UC cells in vitro and in vivo, possibly by inducing apoptosis due to DM1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Small Animal Clinical Medicine, Graduate School of Veterinary Sciences, Osaka Metropolitan University, Osaka, Japan.
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.
- Veterinary Medical Centre, The University of Tokyo, Tokyo, Japan.
- Laboratory of Large Animal Clinical Medicine, Graduate School of Veterinary Sciences, Osaka Metropolitan University, Osaka, Japan.
ORCID-Profile: Kosei Sakai
Förderung
- JSPS KAKENHI
Zitieren
APA
Sakai, K., Kato, D., Yoshinaka, J., Takahashi, Y., Ikeda, N., Aoki, S., Iguchi, T., Ishikawa, S., Yamagishi, N., Shimamura, S., & Nakagawa, T. (2024). Effects of trastuzumab emtansine on canine urothelial carcinoma cells in vitro and in vivo. Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.12970
Vancouver
Sakai K, Kato D, Yoshinaka J, Takahashi Y, Ikeda N, Aoki S, et al. Effects of trastuzumab emtansine on canine urothelial carcinoma cells in vitro and in vivo. Veterinary and Comparative Oncology. 2024. doi:10.1111/vco.12970
BibTeX
@article{Sakai2024,
author = {Sakai, Kosei and Kato, Daiki and Yoshinaka, Junka and Takahashi, Yosuke and Ikeda, Namiko and Aoki, Susumu and Iguchi, Takaaki and Ishikawa, Shingo and Yamagishi, Norio and Shimamura, Shunsuke and Nakagawa, Takayuki},
title = {Effects of trastuzumab emtansine on canine urothelial carcinoma cells in vitro and in vivo},
journal = {Veterinary and Comparative Oncology},
year = {2024},
doi = {10.1111/vco.12970}
}
EUVIMED